http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105380954-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7024 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7024 |
| filingDate | 2015-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-105380954-B |
| titleOfInvention | Application of the tannic acid as HIV-1 latent infection activator |
| abstract | The invention discloses application of the tannic acid as 1 latent infection activator of HIV.Use to incorporate and carried GFP The Jurkat latent infected cells system of the HIV 1 of reporter gene, confirms that tannic acid has the function that activating HIV 1 hides into Drug Storage by high flux screening, causes GFP expression quantity in screening system to raise.And further by the cell model clone strain of multiple 1 latent infections of HIV such as J Lat it is experimentally confirmed that the medicine has the latent effects of good activation HIV 1 really.It the experiment proved that, EC50 of the tannic acid in J Lat cells is 46.63 μM, has the activation effect of preferable 1 latent infections of HIV, and tannic acid has important research and development value and development significance in terms of the activation of 1 latent infections of HIV. |
| priorityDate | 2015-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 29.